Alps Advisors Inc Cara Therapeutics, Inc. Transaction History

Alps Advisors Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$4.89 - $12.27 $4,445 - $11,153	-909 Reduced 2.49%	35,541 $174,000
Q4 2022 Feb 14, 2023	BUY	$8.88 - $12.77 $323,676 - $465,466	36,450 New	36,450 $391,000
Q4 2019 Feb 07, 2020	SELL	$16.11 - $25.98 $1.5 Million - $2.41 Million	-92,860 Closed	0 $0
Q3 2019 Nov 04, 2019	BUY	$18.28 - $26.91 $176,584 - $259,950	9,660 Added 11.61%	92,860 $1.7 Million
Q2 2019 Aug 07, 2019	SELL	$17.68 - $21.57 $213,556 - $260,544	-12,079 Reduced 12.68%	83,200 $1.79 Million
Q1 2019 May 01, 2019	BUY	$14.41 - $19.64 $59,297 - $80,818	4,115 Added 4.51%	95,279 $1.87 Million
Q4 2018 Feb 04, 2019	BUY	$12.45 - $23.47 $1.13 Million - $2.14 Million	91,164 New	91,164 $1.19 Million

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $262M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.